The stock reaction will likely hinge on investor confidence in the 2026 guidance, particularly the dramatic projected recovery in the Interventional Dry Eye segment. Traders should monitor upcoming quarterly results for signs of this recovery materializing.
Price Chart
Executive Summary
Sight Sciences reported Q4 2025 revenue growth of 7% to $20.4M, but full-year 2025 revenue declined 3% to $77.4M due to a significant drop in Interventional Dry Eye sales. However, the company issued strong 2026 guidance projecting revenue growth of 6-14% to $82-88M, driven by a major expected rebound in Dry Eye revenue and continued Glaucoma growth. Despite the mixed 2025 results, the positive forward outlook and improved cash flow dominate the narrative.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $20.4M (+7% YoY)
- Full-year 2025 revenue: $77.4M (-3% YoY)
- Interventional Dry Eye revenue fell from $4.0M in 2024 to $1.6M in 2025
- 2026 revenue guidance: $82M-$88M (+6% to +14% YoY)
- 2026 Interventional Dry Eye guidance: $5M-$7M (up from $1.6M)
- Cash and cash equivalents: $92.0M as of Dec 31, 2025
- Cash used in full year 2025: $28.4M
Financial Impact
Revenue is expected to grow from $77.4M in 2025 to $82-88M in 2026, with a significant rebound in the Interventional Dry Eye segment.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Interventional Glaucoma | $75.7M | 0.0% |
| Interventional Dry Eye | $1.6M | -58.9% |
Risk Factors
- The 2026 guidance is highly ambitious, especially the 3-4x projected growth in Dry Eye revenue, which could be difficult to achieve.
- The full-year 2025 revenue decline and significant drop in Dry Eye sales indicate current business challenges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-091482 |
| Document: sght-20260304.htm | 0001193125-26-091482 |
| Document: sght-ex99_2.htm | 0001193125-26-091482 |
| Document: 0001193125-26-091482-index-headers.html | 0001193125-26-091482 |
| Document: 0001193125-26-091482-index.html | 0001193125-26-091482 |
| Document: 0001193125-26-091482.txt | 0001193125-26-091482 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $9.09 | awaiting T+5 | — | $9.02 (−0.77%) |
Oct 5, 2026 21d ago | Insider Cluster | $8.56 $8.39 | ▼ −1.99% | ▼ −1.85% | $9.02 (+5.37%) |
Aug 10, 2026 11w ago | 8-K | $7.70 $8.24 | ▲ +7.01% | ▲ +7.06% | $9.02 (+17.14%) |
Jul 6, 2026 16w ago | Insider Cluster | $5.35 $5.05 | ▲ +5.61% | ▲ +6.16% | $9.02 (−68.60%) |
Apr 23, 2026 26w ago | 8-K | $4.32 $3.97 | ▼ −8.10% | ▼ −9.58% | $9.02 (+108.80%) |
Apr 21, 2026 26w ago | Press Release | $4.27 $4.30 | ▲ +0.70% | ▲ +0.65% | $9.02 (+111.24%) |
Apr 1, 2026 29w ago | Insider Cluster | $3.66 $3.50 | ▲ +4.37% | ▲ +8.14% | $9.02 (−146.45%) |
Mar 4, 2026 33w ago | 8-K | $3.96 $3.62 | ▼ −8.59% | ▼ −6.35% | $9.02 (+127.78%) |
Mar 4, 2026 33w ago | Press Release | $3.96 $3.62 | ▼ −8.59% | ▼ −6.35% | $9.02 (+127.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers